Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350051 · ClinicalTrials.gov registry record · Phase 2
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 17
- Study locations
NCT00350051: Completed Phase 2 study of Prostate Cancer, sponsored by Bayer.
NCT00350051 is a Phase 2 study of Prostate Cancer that has completed, run by Bayer. The registered enrollment target is 53 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350051, a Phase 2 study of Prostate Cancer, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe and helps to decrease PSA (Prostate-specific antigen) levels.
Conditions Studied
Interventions
- DRUG Sagopilone (ZK 219477) + prednisone
Study Locations (17)
Other
- - Buenos Aires
- - Buenos Aires
- - Buenos Aires
- - Córdoba
California
- - Fountain Valley
Florida
- - Sarasota
Maryland
- - Baltimore
Michigan
- - Ann Arbor
Montana
- - Billings
Nebraska
- - Omaha
New York
- - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2006-08-01 |
| Est. Completion | 2009-12-21 |
| Phase | Phase 2 |
What the finished NCT00350051 record still lists
NCT00350051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sagopilone (ZK 219477) + prednisone is the first listed.
NCT00350051 lists 17 locations in 14 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT00350051 about?
NCT00350051 is a clinical study titled "ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer". The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe and helps to decrease PSA (Prostate-specific antigen) levels.
What is the current status of trial NCT00350051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2006-08-01. Estimated completion is 2009-12-21.
What conditions does trial NCT00350051 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00350051?
The interventions under investigation include: Sagopilone (ZK 219477) + prednisone (DRUG).
Who is sponsoring clinical trial NCT00350051?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00350051 being conducted?
This trial has 17 study locations across California, Florida, Maryland, Michigan, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00350051's enrollment target sits among peer trials
53 463rd of 735 higher than 272 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI